Mark L. Dlugoss

In today's blog from ESCRS, Mark Dlugoss, Ophthalmology Times editor-in-chief, discusses ophthalmic technologies and FDA-related availability issues.

Mark Dlugoss, Ophthalmology Times editor-in-chief, is blogging daily from ESCRS. Today he discusses the attendance of Latin American physicians at ESCRS.

Ophthalmology Times editor-in-chief, Mark Dlugoss, is blogging daily from ESCRS. Today he discusses various releases of intraocular lenses (IOLs).

Ophthalmology Times Editor-in-Chief, Mark Dlugoss, blogs daily from the 2012 congress of the European Society of Cataract and Refractive Surgeons (ESCRS).

A sign of an excellent company is one that capitalizes on its strengths, minimizes its weaknesses, takes advantage of its opportunities, and recognizes its threats, according to James V. Mazzo, president and chief executive officer of Advanced Medical Optics (AMO).

Hideo Ozawa has an aggressive vision for his company. As president and founder of Nidek Inc., Ozawa has set a plan in motion to transform the Japan-based eye-care company to the size of General Motors by the end of the 21st century.

Napa, CA-When Santen Inc. entered the U.S. marketplace, the company's initial corporate campaign featured a bright-eyed, smiling little girl named Molly. The little girl was the focal point of the campaign that was entitled, "Protecting the Joy of Sight."

Fort Worth, TX-Amid the fanfare of the New York Stock Exchange and company executives, Tim Sear of Alcon Laboratories Inc. and Peter Brabeck-Letmathe of Nestl? A stood atop the balcony overlooking the trading floor and rang the opening bell, marking the official start of the day on Wall Street.